Climb Bio Inc (CLYM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $14.32 (+1.85%), Market cap $0.60B, 52-week low–high $1.17 ~ $12.22.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephro
Financial statements, price targets, institutional (13F) holdings and related news for Climb Bio Inc are updated in real time on BlackAll Trade.
Climb Bio Inc trades at $14.32 (+1.85%). Real-time quotes and charts are available on BlackAll Trade.
Climb Bio Inc has a market cap of about $0.60B.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate